Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798465 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL20724764 | 0.85 | CPB2 (0.34) | ALDH1A1KDM4EMAPK1EPHX2 | |
| SCHEMBL20724755 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL20724739 | 0.81 | MAPK1 (0.48) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL19808656 | 0.70 | KDM4E (0.33) | ALDH1A1KDM4ESMN1; SMN2EPHX2HSD11B1 | |
| SCHEMBL19798463 | 0.69 | EPHX2 (0.42) | ALDH1A1KDM4ESMN1; SMN2MAPK1EPHX2 | |
| SCHEMBL12640170 | 0.68 | ALDH1A1 (0.78) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL19807171 | 0.68 | KMT2A (0.56) | ALDH1A1SMN1; SMN2MAPK1EPHX2GAA | |
| SCHEMBL19798445 | 0.67 | MAPK1 (0.56) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL12672463 | 0.67 | ALDH1A1 (0.81) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | ALDH1A1 2128/4885KDM4E 159/4885LMNA 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.